Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Benjamin Morgan Scirica,
Ranolazine is an anti-anginal drug that reduces ischemia via inhibition of the late phase of the inward sodium current, which leads to a reduction in intracellular sodium and calcium overload. Increased intracellular calcium may precipitate electrical instability. In experimental models, ranolazine reduces pro-arrhythmic substrate and triggers, but the potential anti-arrhythmic actions of ranolazine have yet to be demonstrated in humans. The MERLIN-TIMI 36 trial randomized 6560 patients with NSTE-ACS to ranolazine or placebo in addition to standard therapy. Continuous ECG (cECG or Holter) recording was performed for the first 7 days after randomization. A prespecified set of arrhythmias were evaluated by a core laboratory blinded to treatment and outcomes. 6351 pts (97%) had cECG recordings evaluable for arrhythmia analysis. Treatment with ranolazine resulted in significantly lower incidences of arrhythmias. Specifically, fewer patients had an episode of ventricular tachycardia lasting > 8 beats (166 [5.3%] v. 265 [8.3%], p<0.001), supraventricular tachycardia (1413 [44.7%] v. 1752 [55.0%], p<0.001), new-onset atrial fibrillation (55 [1.7%] v.75 [2.4%], p=0.08), or pauses > 3 seconds (97 [3.1%] v. 136 [4.3%], p=0.01).
Among patients admitted with NSTE-ACS, ranolazine reduced the rate of arrhythmias as assessed by cECG monitoring of patients in the first week after admission. These findings support the rationale for future prospective evaluations of ranolazine as an anti-arrhythmic therapy.
Clinical Trial Update II